JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

Search

Allogene Therapeutics Inc

Закрыт

СекторЗдравоохранение

1.22 -4.69

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

1.21

Макс.

1.27

Ключевые показатели

By Trading Economics

Доход

8.8M

-51M

Рентабельность продаж

272,450

Сотрудники

226

EBITDA

-335K

-57M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+664.23% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

6 нояб. 2025 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

48M

273M

Предыдущая цена открытия

5.91

Предыдущая цена закрытия

1.22

Новостные настроения

By Acuity

20%

80%

140 / 373 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Very Strong Bearish Evidence

Allogene Therapeutics Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

29 окт. 2025 г., 23:28 UTC

Популярные акции

Stocks to Watch: Chipotle, Align, Sprouts Farmers Market, Meta

29 окт. 2025 г., 23:07 UTC

Отчет

Prudential PLC 3Q New Business Profit Up 13%

30 окт. 2025 г., 00:00 UTC

Отчет

The Hamptons Luxury Housing Market Is Staging a Comeback for the Ages -- WSJ

30 окт. 2025 г., 00:00 UTC

Отчет

Renesas Electronics 9-Mos Loss Y69.09B Vs Net Y197.30B

30 окт. 2025 г., 00:00 UTC

Отчет

Renesas Electronics 9-Mos Loss Y69.09B Vs Net Y197.30B

29 окт. 2025 г., 23:46 UTC

Обсуждения рынка

Nikkei May Decline Amid Caution Ahead of BOJ Decision -- Market Talk

29 окт. 2025 г., 23:40 UTC

Отчет

Meta Shares Fall on Accelerating AI Spending Despite Record Revenue -- WSJ

29 окт. 2025 г., 23:38 UTC

Обсуждения рынка

Gold Rises on Possible Dip-Buying After Falling on Powell's Remarks -- Market Talk

29 окт. 2025 г., 23:25 UTC

Отчет

Alphabet Stock Jumps on Big Earnings Beat -- Barrons.com

29 окт. 2025 г., 22:51 UTC

Отчет

Google Revenue Soars as AI Boom Lifts Cloud Business -- 2nd Update

29 окт. 2025 г., 22:45 UTC

Отчет

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 6th Update

29 окт. 2025 г., 22:41 UTC

Отчет

Prudential PLC 3Q New Business Profit Up 13% on Year to $705.0M >2378.HK

29 окт. 2025 г., 22:41 UTC

Отчет

Prudential PLC APE Sales Up 10% on Year, to $1.72B >2378.HK

29 окт. 2025 г., 22:09 UTC

Отчет

Microsoft Reports Strong Earning as Azure Cloud Revenue Soars by 40%. The Stock Is Still Down. -- Barrons.com

29 окт. 2025 г., 22:08 UTC

Обсуждения рынка
Отчет

Starbucks Revamps Stores in Pursuit of 'Warm' Atmosphere -- Market Talk

29 окт. 2025 г., 21:58 UTC

Отчет

Alphabet Continues to Allocate More Resources to Waymo, CFO Says

29 окт. 2025 г., 21:58 UTC

Отчет

Alphabet's Google Cloud Backlog Rose on Strong Demand for Enterprise AI, CFO Says

29 окт. 2025 г., 21:57 UTC

Отчет

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 5th Update

29 окт. 2025 г., 21:54 UTC

Отчет

Meta's Margins Are Slipping As AI Costs Mount. The Stock Is Falling. -- Barrons.com

29 окт. 2025 г., 21:46 UTC

Отчет

Alphabet CEO Sees Strong Growth and Momentum for Waymo Continuing in 2026

29 окт. 2025 г., 21:43 UTC

Отчет

Alphabet's Google Cloud Signing Larger Deals, Deepening Relationships With Existing Customers, CEO Says

29 окт. 2025 г., 21:43 UTC

Отчет

Alphabet CEO: More Than 70% of Existing Google Cloud Customers Use AI Products

29 окт. 2025 г., 21:42 UTC

Отчет

IGO 1Q Nova Cash Cost A$6.84/Pound, Up 72% On-Quarter

29 окт. 2025 г., 21:42 UTC

Отчет

IGO 1Q Nova Copper Output 1,377 Tons, Down 41% On-Quarter

29 окт. 2025 г., 21:41 UTC

Отчет

IGO 1Q Nova Nickel Sales 3,320 Tons, Down 5% On-Quarter

29 окт. 2025 г., 21:41 UTC

Отчет

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 4th Update

29 окт. 2025 г., 21:41 UTC

Отчет

Alphabet Signed New Google Cloud Customers Faster in 3Q, CEO Says

29 окт. 2025 г., 21:41 UTC

Отчет

IGO 1Q Nova Nickel Production 3,429 Tons, Down 33% On-Quarter

29 окт. 2025 г., 21:40 UTC

Отчет

IGO: Talks Ongoing With Kwinana JV Partner to Settle on Optimum Pathway For Refinery

29 окт. 2025 г., 21:39 UTC

Отчет

IGO 1Q Kwinana Sustaining, Improvement Capex A$8.3 Million

Сравнение c конкурентами

Изменение цены

Allogene Therapeutics Inc Прогноз

Целевая цена

By TipRanks

664.23% рост

Прогноз на 12 месяцев

Средняя 9.4 USD  664.23%

Максимум 14 USD

Минимум 7 USD

Основано на мнении 10 аналитиков Wall Street, спрогнозировавших целевые цены для Allogene Therapeutics Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

10 ratings

7

Покупка

2

Удержание

1

Продажа

Техническая оценка

By Trading Central

1.18 / 1.69Поддержка и Сопротивление

Краткосрочная

Very Strong Bearish Evidence

Среднесрочная

Weak Bullish Evidence

Долгосрочная

Weak Bearish Evidence

Настроения

By Acuity

140 / 373Рейтинг в Здравоохранение

Новостные настроения

Сильные свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Выше среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
help-icon Live chat